Ajinomoto acquires American medical foods company Cambrooke Therapeutics

Food industry news : Japanese food and chemical company Ajinomoto through its subsidiary Ajinomoto North America has acquired medical foods company Cambrooke Therapeutics for nearly $64 million to enter into the US medical foods market.

Based in Massachusetts, Cambrooke Therapeutics is a therapeutic nutrition company. It provides medical nutrition products across the world for patients with serious, chronic, unmet medical needs.

Cambrooke Therapeutics collaborates with physicians and researchers from different parts of the world to develop, test and market products focused on inborn errors of metabolism and intractable epilepsy.

Prior to its acquisition by Ajinomoto, Cambrooke Therapeutics was controlled by equity firms Galen Partners and Seventure Partners.

Medical food products from Cambrooke Therapeutics. Photo courtesy of Ajinomoto Co., Inc..

Following the transaction, the medical foods company gets access to the global nutrition and ingredient sciences expertise of Ajinomoto along with the latter’s proven flavor and texture-enhancing capabilities in research and development.

Ajinomoto has been developing a broad range of specialty applications of amino acid technologies to contribute to the health and wellness sectors. The Japanese firm has been expanding its solutions for specialty nutrition, better food resources and global sustainability.

Tatsuya Sato, the President of Ajinomoto North America, commenting on Ajinomoto acquisition of Cambrooke Therapeutics, said: “Ajinomoto is deeply dedicated to improving lives through high-quality, good tasting nutrition.

“We looked at many companies in recent years to help us grow in medical nutrition. The team at Cambrooke has been very successful in growing faster than other companies by better meeting the nutritional needs of the customers they serve.”

Cambrooke’s acquisition by Ajinomoto backs the former’s focus on specialty nutrition. It also facilitates a pathway for Cambrooke’s use of the core technologies on metabolic and ketogenic therapy products of Ajinomoto. Cambrooke is also expected to enjoy accelerated development of better nutritional solutions through Ajinomoto’s support  to cover more chronic conditions.

Commenting on Ajinomoto acquisition of Cambrooke Therapeutics, Howard Lossing, the President and Chief Executive Officer of Cambrooke, said: “Ajinomoto’s corporate motto of ‘Eat Well, Live Well.’ is an elegant statement that directly reflects Cambrooke’s mission of improving lives via providing the most delicious and most nutritious medical foods for people with chronic health conditions.

“In joining the Ajinomoto Group, our mission remains unchanged, our team remains in place, and our ability to better meet the needs of our customers expands with access to the enormous R&D capabilities of Ajinomoto.”

Lynn Paolella, the co-founder of Cambrooke added: “I am delighted to join Ajinomoto and to leverage Ajinomoto’s expertise. I have been developing specialty low protein products and medical foods for over 20 years, as well as preparing meals at home for my two children with phenylketonuria (PKU).

“Adding Ajinomoto’s ingredient, flavor and nutrition know-how to Cambrooke’s growing family of products makes the future brighter for all families touched by chronic health conditions.”

For more food industry news and food business news updates, keep following Business-News-Today.com.